BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yilmaz Y. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome? World J Hepatol 2012; 4(12): 332-334 [PMID: 23355910 DOI: 10.4254/wjh.v4.i12.332] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
2 Chon YE, Jung KS, Kim KJ, Joo DJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci 2015;60:234-42. [PMID: 25118979 DOI: 10.1007/s10620-014-3293-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
3 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 21.2] [Reference Citation Analysis]
4 Ampuero J, Aller R, Gallego-durán R, Crespo J, Calleja JL, García-monzón C, Gómez-camarero J, Caballería J, Lo Iacono O, Ibañez L, García-samaniego J, Albillos A, Francés R, Fernández-rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero Gómez M. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology 2020;73:17-25. [DOI: 10.1016/j.jhep.2020.02.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
5 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Reference Citation Analysis]
6 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Pereira CD, Passos E, Severo M, Vitó I, Wen X, Carneiro F, Gomes P, Monteiro R, Martins MJ. Ingestion of a natural mineral-rich water in an animal model of metabolic syndrome: effects in insulin signalling and endoplasmic reticulum stress. Horm Mol Biol Clin Investig 2016;26:135-50. [PMID: 26741353 DOI: 10.1515/hmbci-2015-0033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, Mccullough A, Alkhouri N. Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Dig Dis Sci 2020;65:978-86. [DOI: 10.1007/s10620-019-05700-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
9 Litwak KN, Levin S. Effects of excess dietary fructose on liver pathology study have significant methodologic limitations. Am J Clin Nutr 2014;99:209. [PMID: 24363256 DOI: 10.3945/ajcn.113.074625] [Reference Citation Analysis]
10 Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620 [PMID: 25232454 DOI: 10.4254/wjh.v6.i8.613] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
11 Sabath E, Báez-Ruiz A, Buijs RM. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. Obes Rev. 2015; Jul 27. [Epub ahead of print]. [PMID: 26214605 DOI: 10.1111/obr.12308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
12 Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol 2019;30:865-71. [PMID: 31258135 DOI: 10.5152/tjg.2019.18045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
13 Watanabe M, Fuda H, Okabe H, Joko S, Miura Y, Hui S, Yimin, Hamaoka N, Miki E, Chiba H. Oyster extracts attenuate pathological changes in non-alcoholic steatohepatitis (NASH) mouse model. Journal of Functional Foods 2016;20:516-31. [DOI: 10.1016/j.jff.2015.11.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Celikbilek A, Celikbilek M, Okur A, Dogan S, Borekci E, Kozan M, Gursoy S. Non-alcoholic fatty liver disease in patients with migraine. Neurol Sci. 2014;35:1573-1578. [PMID: 24756192 DOI: 10.1007/s10072-014-1798-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Chandra KS, Bansal M, Nair T, Iyengar SS, Gupta R, Manchanda SC, Mohanan PP, Rao VD, Manjunath CN, Sawhney JP. Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J. 2014;66 Suppl 3:S1-51. [PMID: 25595144 DOI: 10.1016/j.ihj.2014.12.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]